Position: Post-doctoral Associate in Pharmacometrics
Team < Dose individualisation in anticancer drugs > which is a part of the
Cancer Research Center of Toulouse (CRCT) INSERM UMR1037, Toulouse University
Position description: a one year (renewable), full time, post-doctoral
associate position in clinical pharmacokinetics-pharmacodynamics (PK/PD) and
quantitative systems pharmacology (QSP).
This position focuses on population PK/PD analysis in the area of anticancer
therapies. The Post-doc fellow would be invited to get involved in the design,
implementation and analysis of clinical trials for drugs developed in Oncology
and Haematology.
Qualifications required: A solid experience of PK modelling software such as
NONMEM, Monolix, R... would be required. The researcher would collaborate on
different projects with the other members of our multidisciplinary team
(pharmacology, pharmacogenetics, biostatistics, analytical chemistry). The
researcher will have access to all the platforms and administrative facilities
within the CRCT and will supervise students for master degree placements, or
doctoral positions.
How to apply: Please send CV, a letter of interest, and the names and email
addresses of two referees to Etienne Chatelut (Team leader)
[email protected].
CRCT Overview: The brand new 'Oncopole' campus, based in Toulouse (South West
of France), gathers academic, scientific, medical, clinical, technological, and
pharmaceutical research on cancer. Its missions are to improve fundamental
knowledge on all aspects of cancer biology and to provide patients with rapid
access to innovative and individualized treatments. The main actors of Toulouse
Oncopole are: The Cancer Research Center of Toulouse (CRCT), a public research
laboratory supported by Inserm, University Toulouse III-Paul Sabatier and CNRS;
The Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), a cancer
care center. Oncopole is the place where clinicians from IUCT-O, translational
research groups, and basic scientists from CRCT have the ideal environment to
develop their projects.
The following publications give an idea of our research area:
- Schmitt A et al: Factors for hematopoietic toxicity of
carboplatin: refining the targeting of carboplatin systemic exposure. J Clin
Oncol 2010;28:4568-4574 ;
- White-Koning M et al: Population analysis of erlotinib in adults
and children reveals pharmacokinetic characteristics as the main factor
explaining tolerance particularities in children. Clin Cancer Res
2011;17:4862-4871
- Thomas F et al : Genotyping of a family with a novel deleterious
DPYD mutation supports the pretherapeutic screening of DPD deficiency with
dihydrouracil/uracil ratio. Clin Pharmacol Ther.2016 Feb;99(2):235-42.Chalret
du Rieu Q et al: Pharmacokinetic/Pharmacodynamic modeling of
abexinostat-induced thrombocytopenia across different patient populations:
application for the determination of the maximum tolerated doses in both
lymphoma and solid tumour patients. Invest New Drugs. 2014;32:985-94.
- Imbs DC et al: Pharmacokinetics of pazopanib administered in
combination with bevacizumab. Cancer Chemother Pharmacol 2014;73:1189-96.